IRCT20200407046981N33尚未招募未知
Comparative bioequivalence study of the Dutasteride 0.5-mg capsules manufactured by Zahravi Pharmaceutical Company with Dutasteride brand capsules (Avodart®) by GlaxoSmithKline (GSK).
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 60 years（—）
- 性别
- Male
入选标准
- •The weight limit of each volunteer should be between 60 and 100 kg.
- •All volunteers must be non-smokers.
- •They must be healthy in terms of liver, kidney, respiratory system, mental and other general health characteristics that will be assessed.
- •Candidates who have consented to the consent form.
排除标准
- •Known hypersensitivity or idiosyncratic reaction to Dutasteride or any ingredients.
- •Subjects with BP = 90/60 mm/Hg or BP = 140/90 mm/Hg.
- •Regular smoker who smokes more than ten cigarettes daily.
- •Taking any medicine during two weeks before dosing.
研究者
相似试验
招募中
Unknown
Bioequivalence study of Dutasteride/tamsulosin 0.5/0.4 mg capsuleIRCT20200105046010N91Tasnim company24
已完成
1 期
Bioequivalence Study of the Second Generation Dutasteride and Tamsulosin Hydrochloride (HCL) Combination Capsule in Fasted StateUrologic DiseasesNCT02052713GlaxoSmithKline78
已完成
1 期
Bioequivalence Study of the Second Generation Dutasteride and Tamsulosin HCl Combination Capsule in Fed StateUrologic DiseasesNCT02058576GlaxoSmithKline77
尚未招募
不适用
Comparative in vivo evaluation of 2 Desloratadine 5 mg Tablet formulations.IRCT20180620040164N40Darou darman Pars Co.24
尚未招募
Unknown
Comparative in vivo evaluation of 2 Desloratadine 5 mg Tablet formulations.IRCT20180620040164N60Actover Pharmaceutical Co.24